Clinical review report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) indication: multiple sclerosis, relapsing-remitting
The current drug under review, ofatumumab (20 mg/0.4 mL), is indicated for the treatment of adult patients with RRMS with active disease defined by clinical and imaging features. Ofatumumab is a human monoclonal antibody (immunoglobulin G1) that is available as a solution for subcutaneous injection....
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The current drug under review, ofatumumab (20 mg/0.4 mL), is indicated for the treatment of adult patients with RRMS with active disease defined by clinical and imaging features. Ofatumumab is a human monoclonal antibody (immunoglobulin G1) that is available as a solution for subcutaneous injection. The recommended dose is 20 mg, to be initially administered weekly at weeks 0 (beginning of treatment), 1, and 2, followed by monthly dosing starting at week 4. The sponsor has requested reimbursement of ofatumumab as per the indication under review |
|---|---|
| Physical Description: | 1 PDF file (119 pages) illustrations |